CTLA4 and neoplasm: In murine glioma models, combining radiation concurrently with anti-PD-1 and anti-CTLA-4 or 4-1BB (a costimulatory molecule) agonist yielded improved survival and increased tumor-infiltrating leukocyte (TIL) population, compared with either modality alone (24, 47).